References
- Addis A, Sharabi S, Bonati M. Risk classification systems for drug use during pregnancy: are they a reliable source of information? Drug Saf 2000; 23:245–253.
- Abelson PH. California's proposition 65. Science 1987; 237:1553.
- Generali J. Black Box Rx. blackboxrx.com. 2011. 7-4-2011.
- Rossi S, The Australian Medicines Handbook (AMH). 12th Adelaide: Australian Medicines Handbook Pty Ltd; 2011.
- MIMS online – Australian Product Information. www.mimsonline.com.au/. 2011. UCB Medica. 7-4-2011.
- Psychotropic Expert Group and Psychotropic Guidelines. http://etg.tg.com.au/ (6th). 2008. Melbourne, VIC: Therapeutic Guidelines Ltd. 7-4-2011.
- Moeller KE, Shireman TI, Generali J, Rigler S, Mayorga A. Pharmacy students’ knowledge of black box warnings. Am J Pharm Educ 2010; 74:5.
- Australian Regulatory Guidelines for Prescription Medicines. http://www.tga.gov.au/pmeds/argpm.pdf. 2004. Therapeutic Goods Administration. 7-4-2011.
- Medicines Australia Code of Conduct. http://medicinesaustralia.com.au/code-of-conduct/code-of-conduct-current-edition/. 2010. 7-4-2011.
- van der Sijs H, van Gelder T, Vulto A, Berg M, Aarts J. Understanding handling of drug safety alerts: a simulation study. Int J Med Inform 2010; 79:361–369.
- Roughead EE, Gilbert AL, Primrose JG. Improving drug use: a case study of events which led to changes in use of flucloxacillin in Australia. Soc Sci Med 1999; 48:845–853.
- Murphy S, Roberts R. “Black box” 101: how the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk. J Allergy Clin Immunol 2006; 117:34–39.
- Guo JJ, Curkendall S, Jones JK, Fife D, Goehring E, She D. Impact of cisapride label changes on codispensing of contraindicated medications. Pharmacoepidemiol Drug Saf 2003; 12: 295–301.
- Weatherby LB, Nordstrom BL, Fife D, Walker AM. The impact of wording in “Dear doctor” letters and in black box labels. Clin Pharmacol Ther 2002; 72:735–742.
- Office of Product Review, Therapeutic Goods Administration. 2011. 7-4-2011. (Personal Communication)
- Matlock A, Allan N, Wills B, Kang C, Leikin JB. A continuing black hole? The FDA boxed warning: an appeal to improve its clinical utility. Clin Toxicol (Phila). 2011 Jul;49(6):443–7.